Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 10/20 | 0.61 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607425 | 1.00 | ABCG2 (0.61) | ABCG2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL5607658 | 0.98 | ABCG2 (0.59) | ABCG2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL5607688 | 0.98 | ABCG2 (0.59) | ABCG2CA1CA2KDM4EALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL5607438 | 0.98 | ABCG2 (0.64) | ABCG2CA1CA2KDM4EALDH1A1 | |
| Methyl Alcohol SCHEMBL6062257 | 0.98 | ABCG2 (0.59) | ABCG2CA1CA2KDM4EALDH1A1 | |
| Rubidium SCHEMBL5606706 | 0.98 | ABCG2 (0.59) | ABCG2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL5607463 | 0.98 | ABCG2 (0.59) | ABCG2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL5607118 | 0.98 | ABCG2 (0.59) | ABCG2CA1CA2KDM4EALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL5607431 | 0.98 | ABCG2 (0.64) | ABCG2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL5607627 | 0.98 | ABCG2 (0.59) | ABCG2CA1CA2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801093-B1 | Process for the Preparation of enantiomer-enriched 2-Alkoxy-3-Phenyl-Propionic Acid | SALTIGO GMBH (DE) | 2009-03-18 | — | — | EP | disclosed |
| US-7429676-B2 | Process for preparing enantiomerically enriched 2-alkoxy-3-phenylpropionic acids | SALTIGO GMBH (DE) | 2008-09-30 | — | — | US | disclosed |
| US-7429676-B2 | Process for preparing enantiomerically enriched 2-alkoxy-3-phenylpropionic acids | SALTIGO GMBH (DE) | 2008-09-30 | — | — | US | disclosed |
| US-20070149804-A1 | Process for preparing enantiomerically enriched 2-alkoxy-3-phenylpropionic acids | SALTIGO GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149804-A1 | Process for preparing enantiomerically enriched 2-alkoxy-3-phenylpropionic acids | SALTIGO GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| EP-1801093-A1 | Process for the Preparation of enantiomer-enriched 2-Alkoxy-3-Phenyl-Propionic Acid | Saltigo GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1687250-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | Takasago International Corporation (JP) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051882-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-09 | — | — | WO | disclosed |
| US-3975235-A | ESTERASE | MEIJI SEIKA KAISHA, LTD. (JA) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149804-A1 | Process for preparing enantiomerically enriched 2-alkoxy-3-phenylpropionic acids | HPD, PAH, APEH | ABCG2 1910/4885CA1 1209/4885CA2 532/4885 |
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | ALDH1A2, ALDH1A3, GRHPR | ABCG2 3631/4885CA1 329/4885CA2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.